KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Receivables (2016 - 2025)

Gsk (GSK) has 9 years of Receivables data on record, last reported at $9.9 billion in Q4 2024.

  • For Q4 2024, Receivables fell 5.63% year-over-year to $9.9 billion; the TTM value through Dec 2024 reached $9.9 billion, down 5.63%, while the annual FY2024 figure was $9.8 billion, 6.21% down from the prior year.
  • Receivables reached $9.9 billion in Q4 2024 per GSK's latest filing, down from $10.5 billion in the prior quarter.
  • Across five years, Receivables topped out at $12.3 billion in Q4 2021 and bottomed at $8.7 billion in Q4 2020.
  • Average Receivables over 5 years is $10.2 billion, with a median of $9.9 billion recorded in 2024.
  • Peak YoY movement for Receivables: dropped 21.39% in 2020, then soared 41.89% in 2021.
  • A 5-year view of Receivables shows it stood at $8.7 billion in 2020, then soared by 41.89% to $12.3 billion in 2021, then decreased by 21.06% to $9.7 billion in 2022, then grew by 7.75% to $10.5 billion in 2023, then fell by 5.63% to $9.9 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Receivables were $9.9 billion in Q4 2024, $10.5 billion in Q4 2023, and $9.7 billion in Q4 2022.